Genmab — Marts 2026
-
1.620 DKK er teknisk gyldigt som 100% Fib-retracement og et plausibelt worst-case dip i nuværende nedtrend.
Men det er ikke base-case - valuationen er allerede lav (~12-13x P/E), og historisk har Genmab reboundet kraftigt fra lignende oversolgt niveauer.
Opdateret akkumulerings-alert:
Primær zone: 1.680-1.790 DKK (deep dip + tidlig bounce).
Ekstrem zone: 1.620-1.680 DKK (hvis fuld retracement rammer ugekort - stærk value-entry for langsigtede, men høj risiko for yderligere volatilitet).
-
a bit more from Handelsbanken - https://x.com/StockwatchDK/status/2029102074785411113
-
March 05, 2026
The U.S. Food and Drug Administration today approved teclistamab in combination with daratumumab hyaluronidase-fihj, Tec-Dara, to treat adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. https://www.fda.gov/news-events/press-announcements/fda-grants-third-approval-under-national-priority-voucher-program
-
Godmorgen
-
Genmab får sænket kursmål til 2600 kr. fra 2750 kr. hos UBS https://proinvestor.com/investornyt/1418427/genmab-far-saenket-kursmal-til-2600-kr-fra-2750-kr-hos-ubs
-
Genmab: Amerikansk partner får godkendt Darzalex-kombination i knoglemarvskræft https://proinvestor.com/investornyt/1418431/genmab-amerikansk-partner-far-godkendt-darzalex-kombination-i-knoglemarvskraeft
-
Der har jo ikke været logik i aktien i årevis. - Hvorfor skulle det starte nu?..... TAerne har igennem de serene år ramt helt forkert med Genamabs mellemlange til langsigtede kursudvikling. - Håber dog at @Stockbull rammer med hans seneste forecast - det ligner i hvert fald et sandsynligt scenarie...
-
it is what it is gdn55 , not a lot we can do about it... some investors will simply have to sell because of their losses in those 2, others get dragged down with related indices that suffer and some will loose confidence in the biopharma sector althogether... and the middle east certainly doesn't help, i see only red on my screens, except for VIX, gas and oil...
-
#Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell #lymphoma https://x.com/DrRaulCordoba/status/2030026231790326008 https://haematologica.org/article/view/haematol.2025.300086
-
On Tec-Dara, many raving reviews on socials and media like "MajesTEC-3 showed unprecedented efficacy, supporting a new standard of care in relapsed/refractory multiple myeloma patients ... The results represented "the greatest PFS treatment effect we've seen to date," María-Victoria Mateos MD said" https://www.medpagetoday.com/hematologyoncology/myeloma/120201 , but Genmab still lost almost 50dkk..., difficult market...
-
Healio Disruptive Innovators Awards 2026, nominees for the Industry Breakthrough awards (goes to a product that stands out as a major disruption to the practice of hematology/oncology.) , 2 of the 6 are Genmabs , Dara and Epco https://www.surveymonkey.com/r/HealioInnovators
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind